GLB-001
A First-in-human, Phase 1, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
What's the purpose of the trial?
In this study, researchers want to find the best dose of GLB-001 to treat leukemia. The people in this study have acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (HR-MDS) that keeps growing after treatment.
GLB-001 breaks down the CK1-alpha protein, which plays an important role in cancer cell growth and survival. By breaking down this protein, GLB-001 may help slow or stop the growth of AML or HR-MDS. GLB-001 is taken orally (by mouth).
Accepting patients
Participating Centers
There are 4 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- GLB-001 is a kind of medication called a molecular glue degrader. This medication may work by targeting and bringing together proteins on tumor cells and proteins in the human body that break down cells.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.